- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012 Academic Article GET IT
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. The Journal of clinical investigation. 2011 Academic Article GET IT
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
Times cited: 142